Clinical Trials Logo

Pre-diabetes clinical trials

View clinical trials related to Pre-diabetes.

Filter by:

NCT ID: NCT05114018 Completed - Metabolic Syndrome Clinical Trials

Effect of Pasteurized Akkermansia Muciniphila on Insulin Resistance in Otherwise Healthy Subjects With Dysglycaemia

Start date: June 24, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of pasteurized Akkermansia muciniphila (pAKK) in improving insulin sensitivity in hyperglycaemic, but otherwise healthy persons with metabolic syndrome. This is the primary objective of this study. Secondary objectives consist of evaluation of the effects of next generation beneficial microbes on metabolic health, anthropometry and body composition, and safety. Therefore, the trial is designed as a phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center trial comparing pAKK with placebo in restoring insulin sensitivity in dysglycaemic but otherwise healthy subjects with metabolic syndrome. In total, 144 enrolled participants will attend 6 study visits in total. Study visits may be conducted in the clinic, at home by a Healthcare Professional, or by telephone / telemedicine.

NCT ID: NCT05058690 Not yet recruiting - Diabetes Mellitus Clinical Trials

Artificial Intelligence to Improve Cardiometabolic Risk Evaluation Using CT Scans

ACRE-CT
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

To validate the ability of the FatHealth algorithm to identify individuals with pre-diabetes and with type 2 diabetes mellitus

NCT ID: NCT05052918 Recruiting - Atherosclerosis Clinical Trials

The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes

Start date: September 8, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate whether there is a change in carotid intima media thickness with the application of guide-based exercise programs in individuals with prediabetes, and to evaluate whether there is a difference between the group in which exercise programs were applied and those who received only lifestyle change and metformin.

NCT ID: NCT05051436 Recruiting - Obesity Clinical Trials

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Start date: December 13, 2021
Phase: Phase 4
Study type: Interventional

The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.

NCT ID: NCT05041491 Recruiting - Pre-diabetes Clinical Trials

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

BURST2D
Start date: November 30, 2021
Phase: Early Phase 1
Study type: Interventional

Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in people who achieve the recommended levels of PA. Preliminary experimental data suggest that breaking up prolonged sedentary time by performing multiple short bouts (5 min) of PA throughout the day, may improve glycemia more than performing a single continuous bout of PA, and thereby potentially be a novel strategy to prevent T2D. The improvement in glycemia was observed even when the total amount of PA and total energy expenditure were matched, suggesting that how and when PA is performed over the day may matter more than how much PA is done. However, important gaps in knowledge remain including: (1) whether similar benefits on glucose control would be observed in adults with prediabetes, a clinically relevant population that is at high risk of developing T2D; (2) whether these effects are sustained or diluted over time, and (3) what are the mechanistic underpinnings. To address these gaps, the investigators propose to measure the acute and chronic effects of PA breaks on glucose control and the underlying mechanisms in individuals at risk of developing T2D. Sedentary men and women with prediabetes (n=66, 50% F) will be randomized to either an intervention designed to interrupt SB with 5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/week (BREAK) or a control condition consisting of 45-min of brisk walking performed as a single daily continuous bout, 5 days/week (ONE). The two 3-months interventions will be matched for total active time.

NCT ID: NCT05038137 Completed - Breast Cancer Clinical Trials

Time Restricted Eating on Cancer Risk

TREC
Start date: May 4, 2022
Phase: N/A
Study type: Interventional

Participants will be randomly assigned to either the time restricted feeding group with a daily eating period of 8 hours or the control group with a daily eating period of greater than or equal to 12 hours. There are 2 in-person study visits to have blood, urine and vital signs collected and 8 remote or phone visits with a psychologist or dietician to assist with the eating schedule. The study will take last 3 1/2 months.

NCT ID: NCT05008276 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Start date: September 27, 2021
Phase:
Study type: Observational

Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.

NCT ID: NCT04991142 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Models of Nutrition From Continuous Glucose Monitors

Start date: September 17, 2021
Phase:
Study type: Observational

With this study, researchers want to conduct ambulatory studies in which people (healthy, with T2D, or at-risk of T2D) will consume a variety of pre-set and conventional meals in free-living conditions while wearing one or more continuous glucose monitors (CGMs) and, to assess physical activity, a smart watch. With data from these devices, researchers will develop algorithms that can predict the content of a meal.

NCT ID: NCT04978376 Completed - Clinical trials for Overweight and Obesity

TRE With Physical Activity for Weight Management

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Approximately 24 million older adults have prediabetes. Obesity, age related decreases in lean mass and increases in fat mass, and sedentary lifestyle have been associated with functional and cognitive decline in older adults. Innovative lifestyle strategies to treat obesity and pre-diabetes are critically needed. The proposed research will demonstrate that time restricted eating combined with resistance training is an effective non-pharmacological therapy to help obese prediabetic individuals reduce body fat, maintain lean mass, prevent progression of prediabetes to diabetes, and improve cognition.

NCT ID: NCT04938843 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Effect of F. Prausnitzii on Glycemic Control

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

The microbiota is associated with a wide spectrum of diseases including diabetes and non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F. prausnitzii, which is a part of the human gut microbiota, can improve metabolic parameters in subjects with impaired glucose control.